Advertisement

ResMed misses Wall Street's Q2 earnings expectations as U.S. sales fall shorter than projected.

Shares of respiratory devices maker ResMed (NYSE:RMD) dropped more than 6% today after the company reported its Q2 earnings, missing Wall Street's expectations.

ResMed CEO Mick Farrell had his own regrets about the quarter, saying that regulatory issues hindered U.S. sales but that the path ahead looks promising.

Advertisement
Advertisement